DrugRisk NuvaRing Update: Fewer Using Device Amid Warnings, Lawsuits
The Drug Risk ResourceCenter is the Web´s largest source for information on prescription drug warnings, side effects and legal news. Visit http://www.DrugRisk.com
Dallas, TX (PRWEB) February 15, 2013
The birth control safety advocates at DrugRisk.com are alerting those women using NuvaRing contraceptives of new information added to the site which shows several health organizations have warned of blood clot risks from the devices. Also, Merck has reported lower sales of NuvaRing amid increasing patient injury claims.
“DrugRisk´s goal is to improve patient safety by providing the latest drug warnings, recalls, studies and litigation news. In the case of NuvaRing, consumers should know of the recent trend of blood clot warnings and legal claims so they can discuss options with their doctor and decide if they need legal advice ” explains DrugRisk representative Ryan Mayer.
The resource center previously advised patients that experts have linked vaginal ring contraceptives like NuvaRing to higher risks of blood clots than traditional birth control pills. On June 14, 2012, the New England Journal of Medicine published a study finding vaginal ring contraceptives could relate to a 2.5 to 3-fold increased risk of blood clots.*
DrugRisk also recently added information from Brigham and Women´s Faulkner Hospital which found combined hormone vaginal ring contraceptives like NuvaRing can increase blood clot risks for all women, but especially those suffering migraines.**
The resource center has learned that more than 1,000 patients have filed a NuvaRing lawsuit, with many of the cases moved to a special federal court in Missouri. The formal case is known as In re: NuvaRing Products Liability Litigation, No. 08-md-1964, JPML, Eastern District Missouri. New information shows claims have risen nearly 5% in recent months.***
Now, DrugRisk has added information from Merck´s latest financial statements, which show the warnings and legal action may be slowing NuvaRing use. The reports indicate sales decreased from $168 million to $164 million for the fourth quarter of 2012, a drop of over 2% from the previous year.****
Anyone who suffered blood clots, stroke, DVT or pulmonary embolism after using NuvaRing is urged to contact the DrugRisk Resource Center or speak with a lawyer about their legal rights as soon as possible.
Due to the specialized nature of federal MDL drug injury cases, the DrugRisk Center only recommends lawyers and law firms who have already handled NuvaRing lawsuits.
For the original version on PRWeb visit: http://www.prweb.com/releases/prwebnuvaring-lawsuit/nuvaring-side-effects/prweb10434364.htm